FamiCord AG (formerly VITA 34 AG) Overview
Pro stress-test →FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. The company operates in the medical technology sector as a cell bank/stem bank involved in the long-term storage and processing of stem cells from human umbilical cord blood. With over 1 million stored biological material units, the company serves families globally seeking long-term preservation of regenerative cell therapies.
Strategic Profile
Pro stress-test →The company completed group-wide integration projects following the merger of Vita 34 and PBKM subgroups and recently rebranded to FamiCord AG to strengthen international brand presence. The company is active in the areas of Cell & Gene therapies and CDMO (contract development and manufacturing organization). The strategic positioning emphasizes European market dominance with controlled expansion into adjacent cell therapy applications.
Competitive Landscape
Pro stress-test →FamiCord is the leading cell bank in Europe and the third largest worldwide. The company competes in the niche but growing private cord blood banking sector against international players and public healthcare systems. Competitive advantages include 25+ years of operational experience, GMP-certified facilities, European market dominance, and expanding services in cell and gene therapies.
Industry Context
FamiCord AG (formerly VITA 34 AG) operates in Medical Technology / Cell Banking & Regenerative Medicine.
Key facts
Founded: 1997 · Headquarters: Leipzig, Germany · Employees: ~100 · Revenue: EUR 82.2M (2024)